盐酸坦索罗辛治疗前列腺增生症的系统回顾及更新荟萃分析(英文)  

Efficacy and safety of tamsulosin on treating benign prostatic hyperplasia: a systematic review and updated meta-analysis

作　　者：安琪[1,2] 刘德忠[2] 陈一然[3] Russell Smith 刘昂 邹练[2] 

机构地区：[1]中国人民解放军第二炮兵总医院泌尿外科,北京100088 [2]苏州大学中国人民解放军第二炮兵总医院研究生培养基地,北京100088 [3]南方医科大学附属珠江医院血液科,广州510282 [4]奥克兰城市医院泌尿外科

出　　处：《中国性科学》2015年第10期35-46,共12页Chinese Journal of Human Sexuality

摘　　要：目的:利用Meta分析系统观察盐酸坦索罗辛治疗前列腺增生症的疗效。方法:检索Co-chrane图书馆,Embase数据库,Pubmed数据库,中国生物医学文献数据库,CNKI数据库,VIP数据库,万方数据库,纳入盐酸坦索罗辛治疗前列腺增生症的随机对照治疗(RCT),并进行方法学质量评价,采用RevMan5.2软件进行统计分析,并发表偏倚评估和敏感性分析。结果:最终有10篇RCT文献纳入本项研究,Meta分析结果显示盐酸坦索罗辛在IPSS/Boyarsky symptom score,Qmax/MFR以及Qo L score[SMD=-0.34,P<0.00001;WMD=1.10,P<0.00001;WMD=-0.39,P=0.0007]效果方面明显优于安慰剂组(P<0.01),但该药的某些副作用较安慰剂相比亦有显著差别(RR=1.12,P<0.0001)。结论:盐酸坦索罗辛在治疗前列腺增生症中疗效确切,是治疗前列腺增生症的有效方法,但需注意其潜在的副作用。To systematically update and review the efficacy and safety of different dosages of tamsulosin treatments on lower urinary tract symptoms（ LUTS） in male benign prostatic hyperplasia（ BPH） patients to provide more reliable evidence for the use of tamsulosin. Methods： Relevant paper in Pub Med（ 1966 – May 2014）,Embase（ 1974 – May 2014）,the Cochrane Library Database（ 2014,Issue 5） and China National Knowledge Infrastructure（ CNKI）（ 1995- 2014） were reviewed. The assessed outcome measures included international Prostate Symptom Score（ IPSS） / Boyarsky symptom score,quality of life（ QOL） score,maximum flow rate（ MFR / Qmax）and AEs（ adverse events）. Two authors independently assessed the study quality and extracted data. All data were analyzed through Rev Man 5. 2. The meta- analysis included ten randomized controlled trials and the study durations ranged from 4 weeks to 12 weeks. Results： The pooled results showed that the change in the tamsulosin group was significantly higher than the placebo group in the aspects of the IPSS / Boyarsky symptom score,Qmax/ MFR,Qo L score [standardized mean difference（ SMD） =- 0. 34,P〈0. 00001; weighted mean difference（ WMD） = 1. 10,P〈0. 00001; WMD =- 0. 39,P = 0. 0007 respectively]. According to the AEs pooled results,abnormal ejaculation,dizziness,rhinitis（ nasal congestion）,infection,back pain and asthenia / fatigue were the most commonly reported adverse events,and the risk ratio（ RR） of 1. 12 was significantly different from the placebo group（ P〈0.0001）. Conclusion： The current meta- analysis suggests that tamsulosin is effective in treating LUTS of male BPH patients,but its side effects also need further attention.

关 键 词：盐酸坦索罗辛 前列腺增生症 循证医学 荟萃分析 系统回顾 

分 类 号：R562[医药卫生—呼吸系统]